| Original language | English (US) |
|---|---|
| Pages (from-to) | 59 |
| Number of pages | 1 |
| Journal | European Oncology and Haematology |
| Volume | 14 |
| Issue number | 2 |
| State | Published - 2018 |
ASJC Scopus subject areas
- Hematology
- Oncology
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Oncology and Haematology, Vol. 14, No. 2, 2018, p. 59.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Foreword
AU - Kumar, Shaji K.
N1 - Funding Information: Shaji K Kumar, MD, is a consultant in the Division of Hematology at the Mayo Clinic, and Professor of Medicine in the College of Medicine, Mayo Clinic, Rochester, Minnesota, US. He is currently the chair of the National Comprehensive Cancer Network (NCCN) panel on multiple myeloma and is the co-chair of the National Cancer Institute multiple myeloma steering committee. He is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, American Association for Clinical Research, American Society for Blood and Marrow Transplantation, American Medical Association, Association of Physicians of India, and the European Hematology Association. His work has appeared in many peer-reviewed journals such as Lancet Oncology, Journal of Clinical Oncology, Blood Cancer Journal, Leukemia, American Journal of Hematology, Mayo Clinic Proceedings, Blood, and European Journal of Hematology. Dr Kumar’s research efforts are directed toward studying novel treatment approaches in myeloma through well-designed clinical trials. He is principal investigator on multiple phase I, II, and III trials for plasma cell malignancies, which include a combination of Mayo Clinic investigator-initiated trials, industry-sponsored trials, and cooperative group trials. From a translational research standpoint, his laboratory has focused on development of new agents for plasma cell malignancies, with a particular focus on the tumor microenvironment. Dr Kumar receives ongoing support for research from the National Institutes of Health and the National Cancer Institute.
PY - 2018
Y1 - 2018
UR - http://www.scopus.com/inward/record.url?scp=85057789032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057789032&partnerID=8YFLogxK
M3 - Editorial
AN - SCOPUS:85057789032
SN - 2045-5275
VL - 14
SP - 59
JO - European Oncology and Haematology
JF - European Oncology and Haematology
IS - 2
ER -